Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Dr Reddy’s Earnings Plunge On German Unit Charge, Increased Generic Competition

This article was originally published in PharmAsia News

Executive Summary

NEW DELHI - Dr Reddy's Laboratories, India's second-biggest drugmaker, said third quarter earnings and revenues plunged on lower-than-expected earnings in Germany and increased competition as it changes its mix of generic drug products

You may also be interested in...



Dr. Reddy’s Sees Profit Drop As Pricing Pressure Hits Generics Industry

MUMBAI - India's second largest drug maker Dr. Reddy's Laboratories posted a 26 percent drop in quarterly profit partly due to pricing pressures in the generics business

Dr. Reddy’s Sees Profit Drop As Pricing Pressure Hits Generics Industry

MUMBAI - India's second largest drug maker Dr. Reddy's Laboratories posted a 26 percent drop in quarterly profit partly due to pricing pressures in the generics business

Dr Reddy’s Sees Revenue Growth Of 25 Percent This Financial Year, Improved Profitability

NEW DELHI - India's second biggest generic drug maker said it expects revenue growth of 25 percent in the financial year started April and gross margins of 50 percent led by improved cost control at its German betapharm unit and growing revenues from custom manufacturing and active pharmaceutical ingredient sales after earnings below expectations for the fourth quarter ended March

Related Content

UsernamePublicRestriction

Register

OM010563

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel